According to Nova One Advisor, the global cell and gene therapy manufacturing market size is reached at USD 26.67 billion in ...
Universal gene‑edited CAR‑T therapies turn donor T cells into off‑the‑shelf cancer treatments, cutting delays and costs while ...
Under the agreement, participating states will receive “discounts and rebates” from the drugmakers if the treatments don’t ...
ACM impedes the heart from pumping blood to the rest of the body, and is a leading cause of sudden cardiac death in young ...
The global cell and gene therapy market is experiencing explosive growth. Key growth factors include rising chronic/genetic disease prevalence, advancements in gene editing (CRISPR) and viral vectors, ...
At a Food and Drug Administration cell and gene therapy (CGT) roundtable last June, most speakers pushed for the agency to ...
Gene-editing tools like CRISPR have unlocked new treatments for previously uncurable diseases. Now, researchers at the ...
When Genenta Science listed on the Nasdaq at the tail end of 2021, the Milan-based biotech was squarely focused on its pipeline of cell-based gene therapies. | Four years after listing on the Nasdaq, ...
The cell and gene therapy sector has never lacked attention, but all too often, the narrative swings from one extreme to ...
NHS Scotland has approved a one-time CRISPR gene therapy for severe sickle cell disease, offering durable reduction in vaso-occlusive crises for eligible patients.
Potency assays are central to proving a therapy activity and safety, yet for advanced therapies like cell and gene therapies ...
Catalent made a series of deals early this decade to build up its presence in Gosselies. Now, it's planning to wind down cell ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results